Brooklyn Stock Analysis


USD 0.64  0.05  8.47%   

The current slide in stock price could raise concerns from investors as the firm is trading at a share price of 0.64 on 409,068 in volume. The company executives have failed to build on market volatilities in June. However, diversifying your overall positions with Brooklyn Immunotherapeutics may protect your principal portfolio during upcoming market swings. The stock standard deviation of daily returns for 90 days investing horizon is currently 10.09. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Brooklyn Immunotherapeuti partners.
Continue to Trending Equities.
The Brooklyn Immunotherapeuti stock analysis report makes it easy to digest most publicly released information about Brooklyn Immunotherapeuti and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Brooklyn Stock analysis module also helps to analyze the Brooklyn Immunotherapeuti price relationship with some important fundamental indicators such as market cap and management efficiency.

Brooklyn Stock Analysis Notes

About 42.0% of the company shares are held by company insiders. The book value of Brooklyn Immunotherapeuti was currently reported as 0.25. The company recorded a loss per share of 0.45. Brooklyn Immunotherapeuti next dividend is scheduled to be issued on the 29th of November 1970. The entity had 3:1 split on the 26th of March 2021. Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York. Brooklyn Immunotherapeuti operates under Biotechnology classification in the United States and is traded on NYSEMKT Exchange. It employs 10 people. For more info on Brooklyn Immunotherapeutics please contact Michael West at 212 582 1199 or go to

Brooklyn Immunotherapeuti Quarterly Cost of Revenue


Brooklyn Immunotherapeuti Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Brooklyn Immunotherapeuti's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Brooklyn Immunotherapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Brooklyn Immunotherapeuti generated a negative expected return over the last 90 days
Brooklyn Immunotherapeuti has high historical volatility and very poor performance
Brooklyn Immunotherapeuti has some characteristics of a very speculative penny stock
Brooklyn Immunotherapeutics was previously known as BROOKLYN IMMUNOTHERAPEUTICS INC and was traded on NYSEMKT Exchange under the symbol NTN.
The company reported the last year's revenue of 3.45 M. Reported Net Loss for the year was (122.32 M) with profit before taxes, overhead, and interest of 4.69 M.
Brooklyn Immunotherapeutics has about 16.98 M in cash with (23.49 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.3.
Brooklyn Immunotherapeuti has a poor financial position based on the latest SEC disclosures
Roughly 42.0% of the company shares are held by company insiders
Latest headline from MacroaxisInsider: Exercise or conversion by Damour Kevin of 17573 shares of Brooklyn Immunotherapeuti subject to Rule 16b-3

Brooklyn Immunotherapeuti Upcoming and Recent Events

Earnings reports are used by Brooklyn Immunotherapeuti to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Brooklyn Immunotherapeuti previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report10th of March 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End10th of March 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Brooklyn Largest EPS Surprises

Earnings surprises can significantly impact Brooklyn Immunotherapeuti's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Fiscal Date
Estimated EPS
Reported EPS
View All Earnings Estimates

Brooklyn Immunotherapeuti SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Brooklyn Immunotherapeuti prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Brooklyn Immunotherapeuti investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Brooklyn Immunotherapeuti specific information freely available to individual and institutional investors to make a timely investment decision.
17th of June 2022
Financial Statements and Exhibits. Regulation FD Disclosure. Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
7th of June 2022
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
31st of May 2022
Financial Statements and Exhibits. Other Events. Regulation FD Disclosure. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
27th of May 2022
Financial Statements and Exhibits. Regulation FD Disclosure. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
17th of May 2022
Other Events
19th of April 2022
Financial Statements and Exhibits. Changes in Registrant's Certifying Accountant
15th of April 2022
Financial Statements and Exhibits. Regulation FD Disclosure. Results of Operations and Financial Condition
1st of April 2022
Other Events

Brooklyn Immunotherapeuti Thematic Classifications

In addition to having Brooklyn Immunotherapeuti stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Pharmaceutical Products IdeaPharmaceutical Products
USA Equities from Pharmaceutical Products industry as classified by Fama & French

Brooklyn Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Brooklyn Immunotherapeuti is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Brooklyn Immunotherapeutics backward and forwards among themselves. Brooklyn Immunotherapeuti's institutional investor refers to the entity that pools money to purchase Brooklyn Immunotherapeuti's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Armistice Capital LlcCommon Shares5.5 M11.3 M
Blackrock IncCommon Shares2.4 M4.9 M
Cypress Point Wealth Management LlcCommon Shares1.9 M3.9 M
Naviter Wealth LlcCommon Shares1.6 M3.2 M
Vanguard Group IncCommon Shares1.3 M2.6 M
Inverness Counsel LlcCommon Shares1.2 M2.5 M
Jpmorgan Chase CoCommon Shares822.2 K1.7 M
Citadel Advisors LlcCall Options108.7 K223 K
Note, although Brooklyn Immunotherapeuti's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Brooklyn Market Capitalization

The company currently falls under 'Micro-Cap' category with total capitalization of 33.09 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Brooklyn Immunotherapeuti's market, we take the total number of its shares issued and multiply it by Brooklyn Immunotherapeuti's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Brooklyn Profitablity

Brooklyn Immunotherapeuti's profitability indicators refer to fundamental financial ratios that showcase Brooklyn Immunotherapeuti's ability to generate income relative to its revenue or operating costs. If, let's say, Brooklyn Immunotherapeuti is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Brooklyn Immunotherapeuti's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Brooklyn Immunotherapeuti's profitability requires more research than a typical breakdown of Brooklyn Immunotherapeuti's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2022
Return on Investment(22.48) (24.25) 
Return on Average Assets(3.11) (3.20) 
Return on Average Equity(9.73) (9.98) 
Return on Invested Capital(11.73) (12.04) 
Return on Sales(0.10) (0.11) 

Management Efficiency

The entity has Return on Asset of (74.2) % which means that on every $100 spent on asset, it lost $74.2. This is way below average. Brooklyn Immunotherapeuti management efficiency ratios could be used to measure how well brooklyn immunotherapeuti manages its routine affairs as well as how well it operates its assets and liabilities. Return on Investment is likely to drop to -24.25 in 2022. Return on Average Assets is likely to drop to -3.2 in 2022. Brooklyn Immunotherapeuti Current Assets are fairly stable at the moment as compared to the past year. Brooklyn Immunotherapeuti reported Current Assets of 18.77 Million in 2021. Goodwill and Intangible Assets is likely to rise to about 2.1 M in 2022, whereas Total Assets are likely to drop slightly above 26.9 M in 2022.
Last ReportedProjected for 2022
Book Value per Share 0.15  0.15 
Enterprise Value over EBIT(2.30) (2.36) 
Enterprise Value over EBITDA(1.61) (1.65) 
Price to Book Value 33.38  36.01 
Tangible Assets Book Value per Share 0.70  0.72 
Enterprise Value195.9 M211.3 M
Tangible Asset Value30.4 M24.3 M

Technical Drivers

As of the 6th of July, Brooklyn Immunotherapeuti shows the mean deviation of 6.13, and Risk Adjusted Performance of (0.019182). Brooklyn Immunotherapeuti technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate and analyze data for nineteen technical drivers for Brooklyn Immunotherapeutics, which can be compared to its rivals. Please confirm Brooklyn Immunotherapeuti coefficient of variation, maximum drawdown, as well as the relationship between the Maximum Drawdown and skewness to decide if Brooklyn Immunotherapeuti is priced correctly, providing market reflects its regular price of 0.64 per share. As Brooklyn Immunotherapeuti is a penny stock we also strongly suggest to validate its total risk alpha numbers.

Brooklyn Immunotherapeuti Price Movement Analysis

Start Value
Offset on Reverse
AF Init Long
AF Long
AF Max Long
AF Init Short
AF Short
AF Max Short
Execute Study
The output start index for this execution was one with a total number of output elements of three hundred twenty-four. The Extended Parabolic SAR indicator is used to determine the direction of Brooklyn Immunotherapeuti's momentum and the point in time when it has higher than normal probability of directional change. It has more input parameters than standard Parabolic SAR indicator.

Brooklyn Immunotherapeuti Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Brooklyn Immunotherapeuti insiders, such as employees or executives, is commonly permitted as long as it does not rely on Brooklyn Immunotherapeuti's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Brooklyn Immunotherapeuti insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Damour Kevin six days ago via Macroaxis 
Exercise or conversion by Damour Kevin of 17573 shares of Brooklyn Immunotherapeuti subject to Rule 16b-3
Damour Kevin over a week ago via Macroaxis 
Exercise or conversion by Damour Kevin of 17573 shares of Brooklyn Immunotherapeuti subject to Rule 16b-3
Gurrola Sandra M over a week ago via Macroaxis 
Exercise or conversion by Gurrola Sandra M of 8750 shares of Brooklyn Immunotherapeuti subject to Rule 16b-3
Gurrola Sandra M over two weeks ago via Macroaxis 
Payment of 3586 shares by Gurrola Sandra M of Brooklyn Immunotherapeuti subject to Rule 16b-3
Singer Nicholas Jason over three weeks ago via Macroaxis 
Brooklyn Immunotherapeuti exotic insider transaction detected
Jackson Andrew C over three weeks ago via Macroaxis 
Acquisition by Jackson Andrew C of 664800 shares of Brooklyn Immunotherapeuti subject to Rule 16b-3
Angel Matthew over a month ago via Macroaxis 
Brooklyn Immunotherapeuti exotic insider transaction detected
Sidhu Roger over three months ago via Macroaxis 
Acquisition by Sidhu Roger of 142100 shares of Brooklyn Immunotherapeuti subject to Rule 16b-3
Sidhu Roger over three months ago via Macroaxis 
Acquisition by Sidhu Roger of 142100 shares of Brooklyn Immunotherapeuti subject to Rule 16b-3
Sidhu Roger over three months ago via Macroaxis 
Acquisition by Sidhu Roger of 142100 shares of Brooklyn Immunotherapeuti subject to Rule 16b-3
Greenwood Luba over six months ago via Macroaxis 
Acquisition by Greenwood Luba of 67000 shares of Brooklyn Immunotherapeuti subject to Rule 16b-3
Langer Dennis over six months ago via Macroaxis 
Acquisition by Langer Dennis of 67000 shares of Brooklyn Immunotherapeuti subject to Rule 16b-3

Brooklyn Immunotherapeuti Predictive Daily Indicators

Brooklyn Immunotherapeuti intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Brooklyn Immunotherapeuti stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Brooklyn Immunotherapeuti Forecast Models

Brooklyn Immunotherapeuti time-series forecasting models is one of many Brooklyn Immunotherapeuti's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Brooklyn Immunotherapeuti's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Brooklyn Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Brooklyn Immunotherapeuti stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Brooklyn shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Brooklyn Immunotherapeuti. By using and applying Brooklyn Stock analysis, traders can create a robust methodology for identifying Brooklyn entry and exit points for their positions.
Last ReportedProjected for 2022
EBITDA Margin 0.08  0.09 
Gross Margin 0.56  0.57 
Profit Margin(0.12) (0.13) 
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.

Current Brooklyn Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Brooklyn analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Brooklyn analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
14.5Strong Buy2Odds
Brooklyn Immunotherapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Brooklyn analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Brooklyn stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Brooklyn Immunotherapeuti, talking to its executives and customers, or listening to Brooklyn conference calls.
Brooklyn Analyst Advice Details

Brooklyn Stock Analysis Indicators

Brooklyn Immunotherapeutics stock analysis indicators help investors evaluate how Brooklyn Immunotherapeuti stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Brooklyn Immunotherapeuti shares will generate the highest return on investment. By understating and applying Brooklyn Immunotherapeuti stock analysis, traders can identify Brooklyn Immunotherapeuti position entry and exit signals to maximize returns.
Quick Ratio4.80
Fifty Two Week Low0.4600
Shares Short Prior Month2.3M
Average Daily Volume Last 10 Day909.91k
Average Daily Volume In Three Month622.72k
Shares Percent Shares Out4.86%
Short Percent Of Float5.42%
Forward Price Earnings-1.27
Float Shares40.72M
Fifty Two Week High16.3300
Enterprise Value To Ebitda-1.69
Fifty Day Average0.7388
Two Hundred Day Average3.8976
Continue to Trending Equities. Note that the Brooklyn Immunotherapeuti information on this page should be used as a complementary analysis to other Brooklyn Immunotherapeuti's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.

Complementary Tools for Brooklyn Stock analysis

When running Brooklyn Immunotherapeuti price analysis, check to measure Brooklyn Immunotherapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Brooklyn Immunotherapeuti is operating at the current time. Most of Brooklyn Immunotherapeuti's value examination focuses on studying past and present price action to predict the probability of Brooklyn Immunotherapeuti's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Brooklyn Immunotherapeuti's price. Additionally, you may evaluate how the addition of Brooklyn Immunotherapeuti to your portfolios can decrease your overall portfolio volatility.
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Is Brooklyn Immunotherapeuti's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Brooklyn Immunotherapeuti. If investors know Brooklyn will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Brooklyn Immunotherapeuti listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
30.9 M
Return On Assets
Return On Equity
The market value of Brooklyn Immunotherapeuti is measured differently than its book value, which is the value of Brooklyn that is recorded on the company's balance sheet. Investors also form their own opinion of Brooklyn Immunotherapeuti's value that differs from its market value or its book value, called intrinsic value, which is Brooklyn Immunotherapeuti's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Brooklyn Immunotherapeuti's market value can be influenced by many factors that don't directly affect Brooklyn Immunotherapeuti's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Brooklyn Immunotherapeuti's value and its price as these two are different measures arrived at by different means. Investors typically determine Brooklyn Immunotherapeuti value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Brooklyn Immunotherapeuti's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.